-PEG-CO2H + HO-PEG- → -PEG-CO2-PEG- | ester |
-PEG-OPO3H2 + HO-PEG → -PEG-OPO3(H)-PEG- | phosphate ester |
-PEG-CHO + (HO-PEG)2- → -PEG-CH(O-PEG)2- | acetal |
-PEG-CHO + NH2-PEG- → -PEG-CH═N-PEG- | imine |
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/928,049US20020064546A1 (en) | 1996-09-13 | 1997-09-12 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
AT98903545TATE358150T1 (en) | 1997-09-12 | 1998-01-23 | DEGRADABLE POLYETHYLENE GLYCOL HYDRGELS WITH CONTROLLED HALF-LIFE AND THEIR PREPRODUCTS |
AU60293/98AAU6029398A (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
CA002303365ACA2303365C (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
EP98903545AEP1019446B2 (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
ES98903545TES2281925T5 (en) | 1997-09-12 | 1998-01-23 | Degradable polyethylene glycol hydrogels with controlled half-life and precursors thereof |
PCT/US1998/000920WO1999014259A1 (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
PT98903545TPT1019446E (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
DE69837443TDE69837443T3 (en) | 1997-09-12 | 1998-01-23 | DEGRADABLE POLYETHYLENEGLYCOLHYDROGELE WITH CONTROLLED HALF TIME AND ITS PREPARED PRODUCTS |
JP2000511806AJP4083384B2 (en) | 1997-09-12 | 1998-01-23 | Degradable poly (ethylene glycol) hydrogel with controlled half-life and precursor thereof |
DK98903545.6TDK1019446T4 (en) | 1997-09-12 | 1998-01-23 | Degradable poly (ethylene glycol) hydrogels with controlled half-life and precursors thereto |
US10/684,893US7964217B2 (en) | 1996-09-13 | 2003-10-14 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2606696P | 1996-09-13 | 1996-09-13 | |
US08/928,049US20020064546A1 (en) | 1996-09-13 | 1997-09-12 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/684,893ContinuationUS7964217B2 (en) | 1996-09-13 | 2003-10-14 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Publication Number | Publication Date |
---|---|
US20020064546A1true US20020064546A1 (en) | 2002-05-30 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/928,049AbandonedUS20020064546A1 (en) | 1996-09-13 | 1997-09-12 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
US10/684,893Expired - Fee RelatedUS7964217B2 (en) | 1996-09-13 | 2003-10-14 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/684,893Expired - Fee RelatedUS7964217B2 (en) | 1996-09-13 | 2003-10-14 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Country | Link |
---|---|
US (2) | US20020064546A1 (en) |
EP (1) | EP1019446B2 (en) |
JP (1) | JP4083384B2 (en) |
AT (1) | ATE358150T1 (en) |
AU (1) | AU6029398A (en) |
CA (1) | CA2303365C (en) |
DE (1) | DE69837443T3 (en) |
DK (1) | DK1019446T4 (en) |
ES (1) | ES2281925T5 (en) |
PT (1) | PT1019446E (en) |
WO (1) | WO1999014259A1 (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108917A1 (en)* | 2001-09-01 | 2003-06-12 | Nam Huh | Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group |
US20030202955A1 (en)* | 1996-11-06 | 2003-10-30 | Debio Recherche Pharmaceutique S.A. | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
WO2004022629A2 (en)* | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
US20040231886A1 (en)* | 2003-05-20 | 2004-11-25 | Boggs David W. | PCB design and method for providing vented blind vias |
US20070213683A1 (en)* | 1998-11-06 | 2007-09-13 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
US20090215923A1 (en)* | 2008-02-13 | 2009-08-27 | Hyperbranch Medical Technology, Inc. | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates |
US20100268750A1 (en)* | 2007-11-08 | 2010-10-21 | Koninklijke Philips Electronics N.V. | Method and electronic device for managing content |
US8105570B2 (en) | 2001-12-14 | 2012-01-31 | The University Of Wyoming | Methods and compositions for controlled release of drugs |
US8440309B2 (en) | 2011-01-31 | 2013-05-14 | Confluent Surgical, Inc. | Crosslinked polymers with the crosslinker as therapeutic for sustained release |
US9061137B2 (en)* | 2012-10-10 | 2015-06-23 | Korea Institute Of Science And Technology | Nerve electrode provided with anti-inflammatory drug and method of manufacturing the same |
US20150202305A1 (en)* | 2012-09-07 | 2015-07-23 | The Regents Of The University Of California | Method of creating hydrogels through oxime bond fomration |
WO2017200818A1 (en)* | 2016-05-16 | 2017-11-23 | The Trustees Of Columbia University In The City Of New York | Coatings and methods for infection-resistant medical devices |
US9855340B2 (en) | 2012-10-11 | 2018-01-02 | Ascendis Pharma A/S | Hydrogel prodrugs |
US10806144B2 (en) | 2011-11-03 | 2020-10-20 | The Trustees Of Columbia University In The City Of New York | Composition with sustained antimicrobial activity |
US20210162092A1 (en)* | 2018-08-10 | 2021-06-03 | Shanghai Ruining Biotechnology Co. Ltd | Medical hydrogel |
US11041052B2 (en) | 2016-03-31 | 2021-06-22 | Nof Corporation | Biodegradable hydrogel having cyclic benzylidene acetal structure |
CN114767920A (en)* | 2022-05-13 | 2022-07-22 | 中国科学院长春应用化学研究所 | A kind of polyethylene glycol based adhesive and its preparation method and application |
WO2022170681A1 (en)* | 2021-02-09 | 2022-08-18 | 北京光瓴医疗科技有限公司 | Degradable two-component hydrogel, preparation method therefor and use thereof |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566406B1 (en)* | 1998-12-04 | 2003-05-20 | Incept, Llc | Biocompatible crosslinked polymers |
WO1998012274A1 (en) | 1996-09-23 | 1998-03-26 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
US20030191496A1 (en) | 1997-03-12 | 2003-10-09 | Neomend, Inc. | Vascular sealing device with microwave antenna |
US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6514534B1 (en) | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
US6458147B1 (en) | 1998-11-06 | 2002-10-01 | Neomend, Inc. | Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue |
US6994686B2 (en) | 1998-08-26 | 2006-02-07 | Neomend, Inc. | Systems for applying cross-linked mechanical barriers |
US6899889B1 (en) | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
US7279001B2 (en) | 1998-11-06 | 2007-10-09 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
US6949114B2 (en) | 1998-11-06 | 2005-09-27 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
US6830756B2 (en) | 1998-11-06 | 2004-12-14 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
EP2311895B1 (en) | 1999-02-01 | 2017-04-12 | Eidgenössische Technische Hochschule Zürich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US7008635B1 (en) | 1999-09-10 | 2006-03-07 | Genzyme Corporation | Hydrogels for orthopedic repair |
JP4344110B2 (en)* | 1999-10-08 | 2009-10-14 | ネクター セラピューティックス エイエル,コーポレイション | Heterobifunctional polyethylene glycol derivatives and methods for their preparation |
US6413507B1 (en)* | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
JP2003520210A (en)* | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス, インコーポレイテッド | Pharmaceutical formulations for delivery of drugs with low water solubility |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
EP1355965B1 (en) | 2000-10-19 | 2012-09-19 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Method of synthesizing block copolymers for multifunctional self-assembled systems |
US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
EP2305314B1 (en) | 2001-10-10 | 2015-12-23 | ratiopharm GmbH | Remodelling and glycoconjugation of antibodies |
US7045552B2 (en)* | 2002-09-27 | 2006-05-16 | Trimeris, Inc. | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy |
NZ542094A (en) | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
AU2004240553A1 (en) | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
ES2586387T3 (en) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Suitable alpha helical peptides to activate or inhibit cell death |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
CA2551082A1 (en)* | 2004-01-07 | 2005-07-28 | Trimeris, Inc. | Hiv gp41 hr2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus |
AU2005206796B2 (en) | 2004-01-08 | 2011-06-16 | Ratiopharm Gmbh | O-linked glycosylation of peptides |
ES2299776T3 (en) | 2004-06-16 | 2008-06-01 | Straumann Holding Ag | BARRIER MEMBRANE. |
US7282584B2 (en) | 2004-06-16 | 2007-10-16 | Straumann Holding Ag | Methylene blue |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
AU2006203792B2 (en) | 2005-01-10 | 2011-11-03 | Ratiopharm Gmbh | Glycopegylated Granulocyte Colony Stimulating Factor |
AU2006213822B2 (en) | 2005-02-09 | 2011-05-26 | Covidien Lp | Synthetic sealants |
US7517914B2 (en) | 2005-04-04 | 2009-04-14 | Boston Scientificscimed, Inc. | Controlled degradation materials for therapeutic agent delivery |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | FACTOR IX GLYCOPEGYL |
WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
EP1891141B1 (en) | 2005-05-31 | 2016-11-16 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US8367096B2 (en) | 2005-07-19 | 2013-02-05 | Boston Scientific Scimed, Inc. | Polymers having covalently bound therapeutic agents |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP1960447A4 (en) | 2005-12-08 | 2010-12-01 | Tyco Healthcare | Biocompatible surgical compositons |
CA2651793C (en) | 2006-02-02 | 2015-07-07 | Trimeris, Inc. | Hiv fusion inhibitor peptides with improved biological properties |
US7597882B2 (en) | 2006-04-24 | 2009-10-06 | Incept Llc | Protein crosslinkers, crosslinking methods and applications thereof |
US7960498B2 (en)* | 2006-06-30 | 2011-06-14 | Actamax Surgical Materials, Llc | Tissue adhesives with modified elasticity |
CN101516388B (en) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
EP2068907B1 (en) | 2006-10-04 | 2017-11-29 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
PL2118123T3 (en) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
US20090227689A1 (en)* | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227981A1 (en)* | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
JP5052919B2 (en)* | 2007-03-08 | 2012-10-17 | 成均▲館▼大學校 産學協力團 | PH and temperature sensitive block copolymer hydrogel |
EP3159352B1 (en) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
WO2008124406A2 (en) | 2007-04-03 | 2008-10-16 | Neose Technologies, Inc. | Methods of treatment using glycopegylated g-csf |
CN101678125A (en)* | 2007-04-03 | 2010-03-24 | 特里梅里斯公司 | Novel formulations for delivery of antiviral peptide therapeutics |
CN101778859B (en) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | Improved process for the production of nucleotide sugars |
US9125807B2 (en)* | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US8067028B2 (en)* | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
WO2009042194A2 (en)* | 2007-09-25 | 2009-04-02 | Trimeris, Inc. | Methods of synthesis for therapeuthic anti-hiv peptides |
JP5150297B2 (en)* | 2008-02-14 | 2013-02-20 | ネクター セラピューティックス エイエル,コーポレイション | Heterobifunctional polyethylene glycol derivatives and methods for their preparation |
DK2257311T3 (en) | 2008-02-27 | 2014-06-30 | Novo Nordisk As | Conjugated Factor VIII Molecules |
AU2009294875C1 (en) | 2008-09-22 | 2015-05-14 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
JP2012515172A (en) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | Peptidomimetic macrocycle |
CA2750242C (en) | 2009-02-12 | 2018-05-22 | Incept, Llc | Drug delivery through hydrogel plugs |
RU2589254C2 (en) | 2009-06-09 | 2016-07-10 | ПРОЛОНГ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Haemoglobin composition |
WO2011012718A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs comprising an insulin linker conjugate |
WO2011012715A1 (en)* | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
EP2459171B1 (en) | 2009-07-31 | 2017-06-21 | Sanofi-Aventis Deutschland GmbH | Long acting insulin composition |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
AU2010311421B2 (en) | 2009-10-29 | 2014-11-20 | Ascendis Pharma A/S | Sterilization of biodegradable hydrogels |
JP5820815B2 (en) | 2009-12-15 | 2015-11-24 | インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc | Implants and biodegradable fiducial markers |
US8524215B2 (en)* | 2010-08-02 | 2013-09-03 | Janssen Biotech, Inc. | Absorbable PEG-based hydrogels |
WO2012021874A1 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with thioether linkers |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
EP2637680B1 (en) | 2010-11-12 | 2017-03-01 | Dana-Farber Cancer Institute, Inc. | Cancer therapies |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
US9205150B2 (en) | 2011-12-05 | 2015-12-08 | Incept, Llc | Medical organogel processes and compositions |
CA2862391C (en) | 2011-12-29 | 2023-10-10 | Loren D. Walensky | Stabilized antiviral fusion helices |
CN104159595A (en) | 2012-02-15 | 2014-11-19 | 爱勒让治疗公司 | Peptidomimetic macrocycles |
JP6450192B2 (en) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | Triazole-bridged and thioether-bridged peptidomimetic macrocycles |
JP5953459B2 (en)* | 2012-03-27 | 2016-07-20 | ネクター セラピューティクス | Heterobifunctional polyethylene glycol derivatives and methods for their preparation |
US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
SI2920197T1 (en) | 2012-09-26 | 2021-08-31 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
EP2991665A4 (en) | 2013-03-13 | 2016-11-09 | Harvard College | AGRAFES AND SUTURE POLYPEPTIDES AND USES THEREOF |
EP2970392B1 (en) | 2013-03-15 | 2019-07-10 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
CN105492460A (en) | 2013-06-14 | 2016-04-13 | 哈佛大学的校长及成员们 | Stabilized polypeptide insulin receptor modulators |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
WO2015073758A1 (en) | 2013-11-15 | 2015-05-21 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
CN114805527A (en) | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | RAS inhibitory peptides and their uses |
CA2955357A1 (en) | 2014-07-17 | 2016-01-21 | The Regents Of The University Of California | Self-annealing microgel particles for biomedical applications |
CA2961258A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
BR112017005736A2 (en) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | peptidomimetic macrocycles and formulations thereof |
CN107206119B (en) | 2014-12-09 | 2021-01-29 | 实体科学公司 | Medical device coating with biocompatible layer |
AU2016232833A1 (en) | 2015-03-18 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Selective Mcl-1 binding peptides |
MX2017011834A (en) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
WO2016183296A1 (en) | 2015-05-12 | 2016-11-17 | Incept, Llc | Drug delivery from hydrogels |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
MX2017016251A (en) | 2015-07-02 | 2018-04-20 | Dana Farber Cancer Inst Inc | Stabilized anti-microbial peptides. |
US11078246B2 (en) | 2015-08-28 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Peptides binding to Bfl-1 |
CN108368161A (en) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound as MCL-1 conditioning agents |
JP6184462B2 (en)* | 2015-10-28 | 2017-08-23 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Heterobifunctional polyethylene glycol derivatives and methods for their preparation |
WO2017142879A1 (en) | 2016-02-16 | 2017-08-24 | The Regents Of The University Of California | Methods for immune system modulation with microporous annealed particle gels |
CA3014442A1 (en) | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
JP7069126B2 (en) | 2016-08-26 | 2022-05-17 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | BCL-W polypeptides and mimetics for the treatment or prevention of chemotherapy-induced peripheral neuropathy and deafness |
JP7042053B2 (en) | 2016-10-07 | 2022-03-25 | 国立大学法人東京工業大学 | Branched heteromonodisperse polyethylene glycol, its production method, and its conjugate |
CN110446508A (en) | 2016-12-29 | 2019-11-12 | 泰普治疗公司 | For treating the method and system at medical implant position |
WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
JP6361083B2 (en)* | 2017-06-27 | 2018-07-25 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Heterobifunctional polyethylene glycol derivatives and methods for their preparation |
US11325955B2 (en) | 2017-07-19 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
JP7575944B2 (en) | 2017-12-15 | 2024-10-30 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Selective targeting of apoptotic proteins with structure-stabilizing and/or cysteine-responsive NOXA peptides |
CA3089279A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
EP3765852A1 (en) | 2018-03-14 | 2021-01-20 | Dana Farber Cancer Institute, Inc. | Stabilized peptides for biomarker detection |
JP6500318B2 (en)* | 2018-04-04 | 2019-04-17 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Heterobifunctional polyethylene glycol derivative and method for preparing the same |
EP3852783A1 (en) | 2018-09-17 | 2021-07-28 | Massachusetts Institute of Technology | Peptides selective for bcl-2 family proteins |
EP3873435A4 (en)* | 2018-11-02 | 2022-11-09 | Bionaut Labs Ltd. | Magnetomechanic triggering of payload release from miniaturized devices |
EP3962933A1 (en) | 2019-04-18 | 2022-03-09 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
BR112022003689A2 (en)* | 2019-08-29 | 2022-05-24 | Douglas Godfrin Paul | hydrogel matrix |
CN114885599A (en)* | 2019-10-08 | 2022-08-09 | 因库博实验室有限责任公司 | Controlled release formulation delivery device |
AU2020404876A1 (en) | 2019-12-16 | 2022-07-21 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
CA3162922A1 (en) | 2019-12-20 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
US20240124529A1 (en) | 2020-03-04 | 2024-04-18 | Dana-Farber Cancer Institute, Inc. | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF |
US20240131124A1 (en) | 2020-04-22 | 2024-04-25 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
CA3179873A1 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
WO2022098848A1 (en) | 2020-11-05 | 2022-05-12 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
MX2024002824A (en) | 2021-09-08 | 2024-06-28 | Dana Farber Cancer Inst Inc | STRUCTURALLY STAPLED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)-CHOLESTEROL PEPTIDE ANTIVIRAL CONJUGATES AND THEIR USES. |
EP4518900A1 (en) | 2022-05-04 | 2025-03-12 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3149006A (en) | 1963-01-31 | 1964-09-15 | William T Abel | Prevention of embrittlement of metals |
US3419006A (en) | 1966-08-08 | 1968-12-31 | Union Carbide Corp | Novel dressing and use thereof |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3963805A (en) | 1974-10-30 | 1976-06-15 | Union Carbide Corporation | Water swellable poly(alkylene oxide) |
EP0016652B1 (en) | 1979-03-21 | 1985-08-21 | National Research Development Corporation | Composition for the controlled release of an active substance and process for its preparation |
JPS585320A (en) | 1981-07-01 | 1983-01-12 | Toray Ind Inc | Graft copolymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
WO1992000748A1 (en) | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5334640A (en) | 1992-04-08 | 1994-08-02 | Clover Consolidated, Ltd. | Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5514379A (en)† | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
AU4899093A (en) | 1992-10-13 | 1994-04-28 | Pacesetter Ab | Compound and method of applying anti-fouling coatings on medical devices |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
DE4342154A1 (en) | 1993-12-10 | 1995-06-14 | Behringwerke Ag | Amidinophenylalanine derivatives, process for their preparation, their use and agents containing them as anticoagulants |
US5618528A (en) | 1994-02-28 | 1997-04-08 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
US5730968A (en) | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
EP0802787A4 (en)* | 1994-06-17 | 1998-09-02 | Univ Nebraska | IN SITU YELLOWING SUBSTANCE FOR THE ADMINISTRATION OF BIOACTIVE SUBSTANCES AND METHODS OF USE |
WO1996020012A2 (en) | 1994-12-23 | 1996-07-04 | Middlesex Sciences, Inc. | Methods for preparing and purifying macromolecular conjugates |
US5962023A (en)* | 1995-03-06 | 1999-10-05 | Ethicon, Inc. | Hydrogels containing absorbable polyoxaamides |
US5698213A (en)* | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
US5648088A (en) | 1995-03-06 | 1997-07-15 | Ethicon, Inc. | Blends of absorbable polyoxaesters containing amines and/or amide groups |
US5607687A (en) | 1995-03-06 | 1997-03-04 | Ethicon, Inc. | Polymer blends containing absorbable polyoxaesters |
US5597579A (en) | 1995-03-06 | 1997-01-28 | Ethicon, Inc. | Blends of absorbable polyoxaamides |
DK2111876T3 (en) | 1995-12-18 | 2011-12-12 | Angiodevice Internat Gmbh | Crosslinked polymer preparations and methods for their use |
US5610241A (en) | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
EP1053019B1 (en) | 1998-01-07 | 2003-12-03 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030202955A1 (en)* | 1996-11-06 | 2003-10-30 | Debio Recherche Pharmaceutique S.A. | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US7018624B2 (en) | 1996-11-06 | 2006-03-28 | Debio Recherche Pharmaceutique S.A. | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US8802146B2 (en)* | 1998-11-06 | 2014-08-12 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
US20070213683A1 (en)* | 1998-11-06 | 2007-09-13 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
US20100099852A1 (en)* | 1998-11-06 | 2010-04-22 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
US8642085B2 (en)* | 1998-11-06 | 2014-02-04 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
US7695910B2 (en) | 2001-09-01 | 2010-04-13 | Samsung Electronics Co., Ltd. | Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group |
US20070020676A1 (en)* | 2001-09-01 | 2007-01-25 | Nam Huh | Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group |
US20030108917A1 (en)* | 2001-09-01 | 2003-06-12 | Nam Huh | Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group |
US8609080B2 (en) | 2001-12-14 | 2013-12-17 | The University Of Wyoming | Methods and compositions for controlled release of drugs |
US8105570B2 (en) | 2001-12-14 | 2012-01-31 | The University Of Wyoming | Methods and compositions for controlled release of drugs |
US20090264600A1 (en)* | 2002-09-09 | 2009-10-22 | Nektar Therapeutics Al, Corporation | Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid |
US7569214B2 (en) | 2002-09-09 | 2009-08-04 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
KR100967334B1 (en) | 2002-09-09 | 2010-07-05 | 넥타르 테라퓨틱스 | Process for the preparation of water soluble polymer derivatives with terminal carboxylic acids |
US9045494B2 (en) | 2002-09-09 | 2015-06-02 | Nektar Therapeutics | Orthoester compound |
US8182801B2 (en) | 2002-09-09 | 2012-05-22 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
WO2004022629A3 (en)* | 2002-09-09 | 2004-04-08 | Nektar Therapeutics Al Corp | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
US8435504B2 (en) | 2002-09-09 | 2013-05-07 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
US8784791B2 (en) | 2002-09-09 | 2014-07-22 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester |
WO2004022629A2 (en)* | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
US20040231886A1 (en)* | 2003-05-20 | 2004-11-25 | Boggs David W. | PCB design and method for providing vented blind vias |
US20100268750A1 (en)* | 2007-11-08 | 2010-10-21 | Koninklijke Philips Electronics N.V. | Method and electronic device for managing content |
US20090215923A1 (en)* | 2008-02-13 | 2009-08-27 | Hyperbranch Medical Technology, Inc. | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates |
US8410189B2 (en) | 2008-02-13 | 2013-04-02 | Hyperbranch Medical Technology, Inc. | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates |
US8846022B2 (en) | 2008-02-13 | 2014-09-30 | Hyperbranch Medical Technology, Inc. | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates |
US20110044932A1 (en)* | 2008-02-13 | 2011-02-24 | Hyperbranch Medical Technology, Inc. | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates |
US8440309B2 (en) | 2011-01-31 | 2013-05-14 | Confluent Surgical, Inc. | Crosslinked polymers with the crosslinker as therapeutic for sustained release |
US8889889B2 (en) | 2011-01-31 | 2014-11-18 | Confluent Surgical, Inc. | Crosslinked polymers with the crosslinker as therapeutic for sustained release |
US10806144B2 (en) | 2011-11-03 | 2020-10-20 | The Trustees Of Columbia University In The City Of New York | Composition with sustained antimicrobial activity |
US20150202305A1 (en)* | 2012-09-07 | 2015-07-23 | The Regents Of The University Of California | Method of creating hydrogels through oxime bond fomration |
US10201613B2 (en)* | 2012-09-07 | 2019-02-12 | The Regents Of The University Of California | Method of creating hydrogels through oxime bond formation |
US9061137B2 (en)* | 2012-10-10 | 2015-06-23 | Korea Institute Of Science And Technology | Nerve electrode provided with anti-inflammatory drug and method of manufacturing the same |
US9855340B2 (en) | 2012-10-11 | 2018-01-02 | Ascendis Pharma A/S | Hydrogel prodrugs |
US11041052B2 (en) | 2016-03-31 | 2021-06-22 | Nof Corporation | Biodegradable hydrogel having cyclic benzylidene acetal structure |
WO2017200818A1 (en)* | 2016-05-16 | 2017-11-23 | The Trustees Of Columbia University In The City Of New York | Coatings and methods for infection-resistant medical devices |
US20210162092A1 (en)* | 2018-08-10 | 2021-06-03 | Shanghai Ruining Biotechnology Co. Ltd | Medical hydrogel |
WO2022170681A1 (en)* | 2021-02-09 | 2022-08-18 | 北京光瓴医疗科技有限公司 | Degradable two-component hydrogel, preparation method therefor and use thereof |
CN114767920A (en)* | 2022-05-13 | 2022-07-22 | 中国科学院长春应用化学研究所 | A kind of polyethylene glycol based adhesive and its preparation method and application |
Publication number | Publication date |
---|---|
EP1019446B1 (en) | 2007-03-28 |
ES2281925T3 (en) | 2007-10-01 |
AU6029398A (en) | 1999-04-05 |
ES2281925T5 (en) | 2012-04-13 |
DE69837443T3 (en) | 2012-05-24 |
CA2303365A1 (en) | 1999-03-25 |
EP1019446B2 (en) | 2011-11-30 |
JP4083384B2 (en) | 2008-04-30 |
PT1019446E (en) | 2007-06-25 |
EP1019446A1 (en) | 2000-07-19 |
JP2001518528A (en) | 2001-10-16 |
ATE358150T1 (en) | 2007-04-15 |
DE69837443D1 (en) | 2007-05-10 |
WO1999014259A1 (en) | 1999-03-25 |
CA2303365C (en) | 2007-08-21 |
US20040076602A1 (en) | 2004-04-22 |
DK1019446T3 (en) | 2007-07-30 |
US7964217B2 (en) | 2011-06-21 |
DK1019446T4 (en) | 2012-03-19 |
DE69837443T2 (en) | 2008-04-17 |
Publication | Publication Date | Title |
---|---|---|
US7964217B2 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor | |
US7018624B2 (en) | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels | |
US7214388B2 (en) | Degradable heterobifunctional poly(ethylene glycol) acrylates | |
JP2003518526A (en) | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) | |
AU2002328388B2 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment | Owner name:SHEARWATER POLYMERS, INC., ALABAMA Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIS, J. MILTON;REEL/FRAME:009092/0502 Effective date:19980305 | |
AS | Assignment | Owner name:SHEARWATER CORPORATION, ALABAMA Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER POLYMERS, INC.;REEL/FRAME:011295/0671 Effective date:20000927 | |
AS | Assignment | Owner name:DEBIO RECHERCHE PHARMACEUTIQUE S.A., SWITZERLAND Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHEARWATER POLYMERS, INC.;REEL/FRAME:011702/0600 Effective date:20001114 | |
AS | Assignment | Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:013467/0564 Effective date:20021202 | |
AS | Assignment | Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA Free format text:RE-RECORD TO REMOVE SIX APPLICATION AND PATENT NUMBERS INCORRECTLY INCLUDED ON PREVIOUSLY RECORDED DOCUMENT AT REEL 013467 FRAME 0564.;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:014186/0610 Effective date:20021202 | |
STCB | Information on status: application discontinuation | Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION | |
AS | Assignment | Owner name:NEKTAR THERAPEUTICS, CALIFORNIA Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394 Effective date:20090731 Owner name:NEKTAR THERAPEUTICS,CALIFORNIA Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394 Effective date:20090731 |